- Home
- TARS vs DYN Comparison
TARS vs DYN Comparison
Compare TARS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | DYN |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TARS | DYN |
|---|---|---|
| Price | $60.71 | $18.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $89.00 | $37.00 |
| AVG Volume (30 Days) | 614.2K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $8.25 |
| 52 Week High | $85.25 | $25.00 |
Technical Indicators
Market Signals| Indicator | TARS | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 53.45 |
| Support Level | $60.38 | $18.32 |
| Resistance Level | $67.24 | $19.52 |
| Average True Range (ATR) | 3.45 | 0.94 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 34.38 | 80.71 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.